Compare Stocks

→ A new way to collect income from stocks (From DTI) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASPCF Acerus Pharmaceuticals	$0.22	$0.22	$0.22 ▼ $8.16	$1.70M	0.69	1,500 shs	N/A
VIRI Virios Therapeutics	$0.46 +7.0%	$0.41	$0.28 ▼ $2.42	$8.19M	1.88	197,523 shs	53,647 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASPCF Acerus Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
VIRI Virios Therapeutics	+7.20%	+2.82%	+5.98%	+11.17%	-41.21%

It’s now possible to know the win rate of every trade… BEFORE you take it! (Ad)

Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.

>> You can grab your FREE, laminated copies right here <<

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASPCF Acerus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VIRI Virios Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASPCF Acerus Pharmaceuticals	N/A	N/A	N/A	N/A
VIRI Virios Therapeutics	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASPCF Acerus Pharmaceuticals	$2.12M	0.80	N/A	N/A	($3.38) per share	-0.07
VIRI Virios Therapeutics	N/A	N/A	N/A	N/A	$0.20 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASPCF Acerus Pharmaceuticals	-$33.82M	-$3.57	N/A	∞	N/A	-924.33%	N/A	-74.62%	N/A
VIRI Virios Therapeutics	-$5.30M	-$0.28	N/A	N/A	N/A	N/A	-110.15%	-100.18%	5/9/2024 (Estimated)

Latest VIRI, IDH, and ASPCF Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
2/29/2024	Q4 2023	VIRI Virios Therapeutics	-$0.09	-$0.06	+$0.03	-$0.06	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASPCF Acerus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VIRI Virios Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASPCF Acerus Pharmaceuticals	N/A	0.67	0.34
VIRI Virios Therapeutics	N/A	11.60	11.60

Ownership

Institutional Ownership

Company	Institutional Ownership
ASPCF Acerus Pharmaceuticals	N/A
VIRI Virios Therapeutics	9.05%

Insider Ownership

Company	Insider Ownership
ASPCF Acerus Pharmaceuticals	N/A
VIRI Virios Therapeutics	11.70%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ASPCF Acerus Pharmaceuticals	14	7.71 million	N/A	Not Optionable
VIRI Virios Therapeutics	4	19.26 million	17.01 million	Optionable

VIRI, IDH, and ASPCF Headlines

Source	Headline
	Virios Therapeutics, Inc. (VIRI) finance.yahoo.com - April 14 at 7:23 PM
	Virios Therapeutics seeks global patent for antiviral combo investing.com - March 28 at 11:45 PM
	Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID globenewswire.com - March 26 at 9:15 AM
	Virios Therapeutics announces salary cuts for employees and board investing.com - February 29 at 5:35 PM
	Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results markets.businessinsider.com - February 29 at 12:35 PM
	Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results globenewswire.com - February 29 at 9:15 AM
	Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones markets.businessinsider.com - February 28 at 11:24 AM
	Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones globenewswire.com - February 28 at 9:15 AM
	Virios Therapeutics Llc (VIRI) investing.com - February 27 at 7:37 AM
	Virios Therapeutics (VIRI) Price Target Increased by 14.29% to 4.08 msn.com - February 25 at 12:10 AM
	Virios Therapeutics Inc Ordinary Shares VIRI morningstar.com - February 9 at 12:13 AM
	VIRI: Moving IMC-2 into Phase 2 Program in Long COVID finance.yahoo.com - February 7 at 1:09 PM
	Fibromyalgia Treatment Market revenue to cross USD 536 Million by 2033, says Research Nester finance.yahoo.com - February 6 at 3:37 PM
	Virios Therapeutics Stock (NASDAQ:VIRI) Dividends: History, Yield and Dates benzinga.com - January 23 at 10:37 PM
	Virios Therapeutics to advance development of IMC-2 as treatment for symptoms associated with long-Covid pharmabiz.com - January 23 at 7:35 AM
	Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID finanznachrichten.de - January 22 at 3:19 PM
	Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID finance.yahoo.com - January 22 at 10:18 AM
	Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development ... bakersfield.com - January 2 at 9:21 AM
	Virios Therapeutics Reports Receipt Of FDA's Feedback On Requirements For Advancing IMC-2 markets.businessinsider.com - January 2 at 9:21 AM
	Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID finance.yahoo.com - January 2 at 9:21 AM
	Taking a Closer Look At Virios Therapeutics Inc (VIRI) Following Its Recent Trade knoxdaily.com - January 1 at 8:34 AM
	Virios Therapeutics Inc Ordinary Shares morningstar.com - December 7 at 10:47 PM
	Virios Therapeutics, Inc. (NASDAQ:VIRI) Q3 2023 Earnings Call Transcript finance.yahoo.com - November 14 at 1:38 PM
	VIRI: Provides Overview of Phase 3 Program in Fibromyalgia finance.yahoo.com - November 13 at 3:00 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Acerus Pharmaceuticals

OTCMKTS:ASPCF

Acerus Pharmaceuticals Corp. is a pharmaceutical company. The firm is focused on the commercialization and development of prescription products that improve patient experience, with a focus in the field of men's health. It focuses on therapeutics for urology, andrology, and endocrinology. Its products include Estrace and Natesto. The company was founded by Bruce D. Brydon, Rolf K. Reininghaus and Mark L. Thompson on September 9, 2008 and is headquartered in Mississauga, Canada.

Virios Therapeutics

NASDAQ:VIRI

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial